12.3 )] . polyvalent cations deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between ferriprox and other medications (e.g., antacids), or supplements containing these polyvalent cations [see dosage and administration ( 2.2 )] .

immediately interrupt therapy and report to their physician if they experience any symptoms indicative of infection. the incidence of agranulocytosis was 1.7% of patients in pooled clinical trials of 642 patients with thalassemia syndromes and 1.5% of patients in pooled clinical trials of 196 patients with sickle cell disease or other anemias. the mechanism of ferriprox-associated agranulocytosis is unknown. agranulocytosis and neutropenia usually resolve upon discontinuation of ferriprox, but there have been reports of agranulocytosis leading to death. implement a plan to monitor for and to manage agranulocytosis and neutropenia prior to initiating ferriprox treatment. for agranulocytosis (anc < 0.5 x 10 9 /l): consider hospitalization and other management as clinically appropriate. do not resume ferriprox in patients who have developed agranulocytosis unless potential benefits outweigh potential risks. do not rechallenge patients who have developed neutropenia with ferriprox unless potential benefits outweigh potential risks. for neutropenia (anc < 1.5 x 10 9 /l and > 0.5 x 10 9 /l): instruct the patient to immediately discontinue ferriprox and all other medications with a potential to cause neutropenia. obtain a complete blood cell (cbc) count, including a white blood cell (wbc) count corrected for the presence of nucleated red blood cells, an absolute neutrophil count (anc), and a platelet count daily until recovery (anc ≥ 1.5 x 10 9 /l). 5.2 liver enzyme elevations in pooled clinical trials, 7.5% of 642 patients with thalassemia syndromes treated with ferriprox developed increased alt values. four (0.62%) ferriprox-treated subjects discontinued the drug due to increased serum alt levels and 1 (0.16%) due to an increase in both alt and ast. in pooled clinical trials, 7.7% of 196 patients with sickle cell disease or other anemias treated with ferriprox developed increased alt values. monitor serum alt values monthly during therapy with ferriprox and consider interruption of therapy if there is a persistent increase in the serum transaminase levels [see dosage and administration ( 2.1 )] . 5.3 zinc deficiency decreased plasma zinc concentrations have been observed on ferriprox therapy. monitor plasma zinc annually, and supplement in the event of a deficiency [see dosage and administration ( 2.1 )]. 5.4 embryo-fetal toxicity based on findings from animal reproduction studies and evidence of genotoxicity, ferriprox can cause fetal harm when administered to a pregnant woman. the available data on the use of ferriprox in pregnant women are insufficient to inform risk. in animal studies, administration of deferiprone during the period of organogenesis resulted in embryo-fetal death and malformations at doses lower than equivalent human clinical doses. advise pregnant women and females of reproductive potential of the potential risk to the fetus [see use in specific populations ( 8.1 )] . advise females of reproductive potential to use an effective method of contraception during treatment with ferriprox and for at least six months after the last dose. advise males with female partners of reproductive potential to use effective contraception during treatment with ferriprox and for at least three months after the last dose [see use in specific populations ( 8.1 , 8.3 )].

2 ) maximum oral dosage: 99 mg/kg/day (actual body weight) in three divided doses ( 2.2 ) 2.1 important dosage and administration information ferriprox tablets are available in two different 1,000 mg formulations and a 500 mg formulation, which have different oral dosing regimens to achieve the same total daily dosage. ferriprox tablets (twice a day) - 1,000 mg - given two times a day [see dosage and administration ( 2.2 )] ferriprox tablets (three times a day) - 1,000 mg - given three times a day [see dosage and administration ( 2.3 )] ferriprox tablets - 500 mg - given three times a day [see dosage and administration ( 2.4 )] to prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen. each tablet has distinct identifying characteristics [see dosage forms and strengths ( 3 )]. for patients who have trouble swallowing tablets, consider the use of ferriprox oral solution (see the prescribing information for ferriprox oral solution). monitoring for safety due to the risk of agranulocytosis, monitor anc before and during ferriprox therapy. test anc prior to start of ferriprox therapy and monitor on the following schedule during treatment: first six months of therapy: monitor anc weekly; next six months of therapy: monitor anc once every two weeks; after one year of therapy: monitor anc every two to four weeks (or at the patient's blood transfusion interval in patients that have not experienced an interruption due to any decrease in anc [see warnings and precautions ( 5.1 )] . due to the risk of hepatic transaminase elevations, monitor alt before and monthly during ferriprox therapy [see warnings and precautions ( 5.2 )] . due to the risk of zinc deficiency, monitor zinc levels before and regularly during ferriprox therapy [see warnings and precautions ( 5.3 )] . 2.2 recommended dosage for 1,000 mg ferriprox tablets (twice a day) for adult and pediatric patients with transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias starting dosage for twice a day tablets the recommended starting oral dosage of ferriprox tablets (twice a day) is 75 mg/kg/day (actual body weight) in two divided doses per day (taken approximately 12 hours apart), with food. round the total daily dose to the nearest 500 mg (half-tablet). table 1 describes the number of ferriprox tablets (twice a day) needed to achieve the 75 mg/kg/day total starting daily dosage. table 1: number of ferriprox 1,000 mg tablets (twice a day) needed to achieve the total starting daily dosage of 75 mg/kg (rounded to the nearest half-tablet) body weight (kg) morning evening 20 0.5 1 30 1 1.5 40 1.5 1.5 50 2 2 60 2 2.5 70 2.5 3 80 3 3 90 3.5 3.5 to minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved. dosage adjustments for twice a day tablets tailor dosage adjustments of ferriprox tablets (twice a day) to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden). the maximum total daily oral dosage is 99 mg/kg (actual body weight) divided into two doses taken approximately 12 hours apart with food. table 2 describes the number of ferriprox tablets (twice a day) needed to achieve the 99 mg/day total maximum daily dosage. table 2: number of ferriprox 1,000 mg tablets (twice a day) needed to achieve a total maximum recommended daily dosage of 99 mg/kg (rounded to the nearest half-tablet) body weight (kg) morning evening 20 1 1 30 1.5 1.5 40 2 2 50 2.5 2.5 60 3 3 70 3.5 3.5 80 4 4 90 4.5 4.5 2.3 recommended dosage for 1,000 mg ferriprox tablets (three times a day) for adult and pediatric patients with transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias starting dosage for three times a day tablets the recommended starting oral dosage of ferriprox tablets (three times a day) is 75 mg/kg/day (actual body weight), in three divided doses per day. table 3 describes the number of ferriprox tablets (three times a day) needed to achieve the 75 mg/kg/day total starting dosage). round dose to the nearest 500 mg (half-tablet). table 3: number of ferriprox 1,000 mg tablets (three times a day) needed to achieve the total starting daily dosage of 75 mg/kg (rounded to the nearest half-tablet) body weight (kg) morning midday evening 20 0.5 0.5 0.5 30 1 0.5 1 40 1 1 1 50 1.5 1 1.5 60 1.5 1.5 1.5 70 2 1.5 2 80 2 2 2 90 2.5 2 2.5 to minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved. dosage adjustments for three times daily tablets tailor dosage adjustments for ferriprox tablets (three times a day) to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden). the maximum oral dosage is 99 mg/kg/day (actual body weight), in three divided doses per day. table 4 describes the number of ferriprox tablets (three times a day) needed to achieve the 99 mg/day total maximum daily dosage. table 4: number of ferriprox 1,000 mg tablets (three times a day) needed to achieve the maximum total daily dosage of 99 mg/kg (rounded to the nearest half-tablet) body weight (kg) morning midday evening 20 0.5 0.5 1 30 1 1 1 40 1.5 1 1.5 50 1.5 1.5 2 60 2 2 2 70 2.5 2 2.5 80 2.5 2.5 3 90 3 3 3 2.4 recommended dosage for 500 mg ferriprox tablets (three times a day) for adult and pediatric patients with transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias starting dosage for three times a day tablets the recommended starting oral dosage of ferriprox tablets (three times a day) is is 75 mg/kg/day (actual body weight), in three divided doses per day. table 5 describes the number of ferriprox tablets (three times a day) needed to achieve the 75 mg/kg/day total starting dosage. round dose to the nearest 250 mg (half-tablet). table 5: number of ferriprox 500 mg tablets (three times a day) needed to achieve the total starting daily dosage of 75 mg/kg dose (rounded to the nearest half-tablet) body weight (kg) morning midday evening 20 1 1 1 30 1.5 1.5 1.5 40 2 2 2 50 2.5 2.5 2.5 60 3 3 3 70 3.5 3.5 3.5 80 4 4 4 90 4.5 4.5 4.5 to minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved. dosage adjustments tailor dosage adjustments for ferriprox tablets (three times a day) to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden). the maximum oral dosagee is 99 mg/kg/day (actual body weight), in three divided doses per day. table 6 describes the number of ferriprox tablets (three times a day) needed to achieve the 99 mg/day total maximum daily dosage. table 6: number of ferriprox 500 mg tablets (three times a day) needed to achieve the maximum total daily dosage of 99 mg/kg dose (rounded to the nearest half-tablet) body weight (kg) morning midday evening 20 1.5 1 1.5 30 2 2 2 40 3 2 3 50 3.5 3 3.5 60 4 4 4 70 5 4.5 4.5 80 5.5 5 5.5 90 6 6 6 2.5 monitoring ferritin levels to assess efficacy monitor serum ferritin concentration every two to three months to assess the effect of ferriprox on body iron stores. if the serum ferritin is consistently below 500 mcg/l, consider temporarily interrupting ferriprox therapy until serum ferritin rises above 500 mcg/l. 2.6 dosage modification for drug interactions allow at least a 4-hour interval between administration of ferriprox and other drugs or supplements containing polyvalent cations such as iron, aluminum, or zinc [see drug interactions ( 7.2 ), clinical pharmacology ( 12.3 )] .

xperience because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. ferriprox tablets (twice a day) were evaluated in trials in healthy subjects. ferriprox tablets (twice a day) contain deferiprone, the same active ingredient as ferriprox tablets (deferiprone) (three times a day) and ferriprox oral solution (deferiprone). the following adverse reaction information represents the pooled data collected from single arm or active-controlled clinical trials with ferriprox tablets (deferiprone) (three times a day) or ferriprox oral solution (deferiprone). thalassemia syndromes the safety of ferriprox was evaluated in the pooled clinical trial database [see clinical studies ( 14.1 )] . patients received ferriprox tablets (three times a day) or ferriprox oral solution . ferriprox was administered orally three times a day (total daily dose either 50, 75, or 99 mg/kg), n=642. among 642 patients receiving ferriprox, 492 (76.6%) were exposed for 6 months or longer and 365 (56.9%) were exposed for greater than one year. the median age of patients who received ferriprox was 19 years (range 1, 77 years); 50.2% female; 71.2% white, 17.8% asian, 9.2% unknown, 1.2% multi-racial and 0.6% black. the most serious adverse reaction reported in clinical trials with ferriprox was agranulocytosis [see warnings and precautions ( 5.1 )] . the most common adverse reactions (≥6%) reported during clinical trials were nausea, vomiting, abdominal pain, arthralgia, alanine aminotransferase increased and neutropenia. the table below lists the adverse drug reactions that occurred in at least 1% of patients treated with ferriprox in clinical trials in patients with thalassemia syndromes. table 7: adverse reactions occurring in ≥ 1% of ferriprox-treated patients with thalassemia syndromes body system adverse reaction (n=642) % patients blood and lymphatic system disorders neutropenia 6 agranulocytosis 2 gastrointestinal disorders nausea 13 abdominal pain/discomfort 10 vomiting 10 diarrhea 3 dyspepsia 2 investigations alanine aminotransferase increased 7 weight increased 2 aspartate aminotransferase increased 1 metabolism and nutrition disorders increased appetite 4 decreased appetite 1 musculoskeletal and connective tissue disorders arthralgia 10 back pain 2 pain in extremity 2 arthropathy 1 nervous system disorders headache 2 gastrointestinal symptoms such as nausea, vomiting, and abdominal pain were the most frequent adverse reactions reported by patients participating in clinical trials and led to the discontinuation of ferriprox therapy in 1.6% of patients. chromaturia (reddish/brown discoloration of the urine) is a result of the excretion of iron in the urine. sickle cell disease or other anemias the safety of ferriprox compared to deferoxamine was evaluated in la38-0411 [see clinical studies ( 14.2 )] . patients received ferriprox tablets or ferriprox oral solution orally three times a day (total daily dose 75-99 mg/kg/day) n=152) or the control arm, deferoxamine, 20-40 mg/kg/day (children) or 40-50 mg/kg/day (adults), by subcutaneous infusion for 5 – 7 days per week, n=76. among 152 patients receiving ferriprox, 120 (78.9%) were exposed for 6 months or longer and 17 (11.2%) were exposed for greater than one year. the median age of patients who received ferriprox was 15 years (range 3, 59 years); 54.6% male; 78.9% white, 15.1% black and 5.9% multi-racial. the most common adverse reactions (≥6%) reported during clinical trials in patients with scd or other anemias were pyrexia, abdominal pain, bone pain, headache, vomiting, pain in extremity, sickle cell anemia with crisis, back pain, alanine aminotransferase (alt) increased, aspartate aminotransferase (ast) increased, arthralgia, oropharyngeal pain, nasopharyngitis, neutrophil count decreased, cough and nausea. the table below lists the adverse reactions (irrespective of a causal assessment; adverse events) of interest that occurred in patients treated with ferriprox in clinical trials in subjects with sickle cell disease or other anemias. table 8: adverse reactions occurring in ≥5% of ferriprox-treated patients with sickle cell disease or other anemias *grouped term body system adverse reaction ferriprox (n=152) % patients deferoxamine (n=76) % patients blood and lymphatic system disorders sickle cell anemia with crisis 17 13 gastrointestinal disorders abdominal pain* 26 13 vomiting 19 11 nausea 7 9 diarrhea 5 8 general disorders and administration site conditions pyrexia 28 33 pain 5 4 infections and infestations nasopharyngitis 9 12 upper respiratory tract infection 5 3 investigations alanine aminotransferase increased 12 0 aspartate aminotransferase increased 11 0 neutrophil count decreased 8 4 musculoskeletal and connective tissue disorders bone pain 25 34 pain in extremity 18 15 back pain 13 18 arthralgia 10 8 nervous system disorders headache 20 13 respiratory, thoracic and mediastinal disorders oropharyngeal pain 10 15 cough 8 15 clinically relevant adverse reactions in <5% of patients include neutropenia and agranulocytosis. pediatric patients ferriprox has been studied in 86 pediatric patients with sickle cell disease or other anemias. pediatric patients (<17 years) had an increase in the following adverse reactions as compared to adults: abdominal pain, neutrophil count decreased, bone pain and oropharyngeal pain. 6.2 postmarketing experience the following additional adverse reactions have been reported in patients receiving ferriprox. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. blood and lymphatic system disorders: thrombocytosis, pancytopenia. cardiac disorders: atrial fibrillation, cardiac failure. congenital, familial and genetic disorders: hypospadias. eye disorders: diplopia, papilledema, retinal toxicity. gastrointestinal disorders: enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement. general disorders and administration site conditions: chills, edema peripheral, multi-organ failure. hepatobiliary disorders: jaundice, hepatomegaly. immune system disorders: anaphylactic shock, hypersensitivity. infections and infestations: cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess. investigations: blood bilirubin increased, blood creatinine phosphokinase increased. metabolism and nutrition disorders: metabolic acidosis, dehydration. musculoskeletal and connective tissue disorders: myositis, chondropathy, trismus. nervous system disorders: cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence. psychiatric disorders: bruxism, depression, obsessive-compulsive disorder. renal disorders: glycosuria, hemoglobinuria. respiratory, thoracic and mediastinal disorders: acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism. skin, subcutaneous tissue disorders: hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, henoch-schönlein purpura. vascular disorders: hypotension, hypertension.

12.3 )] . polyvalent cations deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between ferriprox and other medications (e.g., antacids), or supplements containing these polyvalent cations [see dosage and administration ( 2.2 )] .

ral population, the estimated background risk of major birth defects and of miscarriage is 2-4% and 15-20%, respectively. data human data post-marketing data available from 39 pregnancies of deferiprone-treated patients and 10 pregnancies of partners of deferiprone-treated patients are as follows: of the 39 pregnancies in deferiprone-treated patients, 23 resulted in healthy newborns, 6 ended in spontaneous abortion, 9 had unknown outcomes, and 1 infant was born with anal atresia, nephroptosis, ventricular septal defect, hemivertebra and urethral fistula. of the 10 pregnancies in partners of deferiprone-treated patients, 5 resulted in healthy newborns, 1 resulted in a healthy newborn with slight hypospadias, 1 was electively terminated, 1 resulted in the intrauterine death of twins, and 2 had unknown outcomes. animal data during organogenesis, pregnant rats and rabbits received deferiprone at oral doses of 0, 30, 80 or 200 mg/kg/day, and 0, 10, 50, or 150 mg/kg/day, respectively. the daily dose was administered as two equal divided doses approximately 7 hours apart. doses of 200 mg/kg/day in rats and 150 mg/kg/day in rabbits, approximately 33% and 49% of the mrhd, respectively, resulted in increased post-implantation loss and reduced fetal weights in the presence of maternal toxicity (reduced maternal body weight and body weight gain in both rats and rabbits; abnormal large placenta at low incidence in rats). the 200 mg/kg/day dose in rats resulted in external, visceral and skeletal fetal malformations such as cranial malformations, cleft palate, limb malrotation, anal atresia, internal hydrocephaly, anophthalmia and fused bones. the dose of 150 mg/kg/day in rabbits resulted in external fetal malformations (partially opened eyes) and minor blood vessel and skeletal variations. in rats, malformations including micrognathia and persistent ductus arteriosus could be observed in the absence of maternal toxicity at doses equal to or greater than 30 and 80 mg/kg/day, approximately 5% and 13% of the mhrd, respectively. 8.2 lactation risk summary there is no information regarding the presence of deferiprone in human milk, the effects on the breastfed child, or the effects on milk production. because of the potential for serious adverse reactions in the breastfed child, including the potential for tumorigenicity shown for deferiprone in animal studies, advise patients that breastfeeding is not recommended during treatment with ferriprox, and for at least 2 weeks after the last dose. 8.3 females and males of reproductive potential pregnancy testing pregnancy testing is recommended for females of reproductive potential prior to initiating ferriprox. contraception females ferriprox can cause embryo-fetal harm when administered to a pregnant woman [see use in specific populations ( 8.1 )] . advise female patients of reproductive potential to use effective contraception during treatment with ferriprox and for at least 6 months after the last dose. males based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with ferriprox and for at least 3 months after the last dose [see nonclinical toxicology ( 13.1 )] . 8.4 pediatric use the safety and effectiveness of ferriprox for the treatment of transfusional iron overload due to thalassemia syndromes have been established in pediatric patients 8 years of age and older. use of ferriprox for this indication is supported by evidence of efficacy from clinical trials in adult patients with thalassemia and evidence of safety in pediatric patients with sickle cell disease. the safety and effectiveness of ferriprox for the treatment of transfusional iron overload due to sickle cell disease or other anemias have been established in 86 pediatric patients 3 to 16 years of age, among the 152 patients treated with ferriprox tablets or oral solution in an adequate and well-controlled study [see adverse reactions ( 6.1 ) and clinical studies ( 14.2 )] . the study included 56 patients 3 to <12 years of age and 30 patients 12 to 16 years of age. seventy-six percent of these patients had sickle cell disease. the recommended starting dose and dose-modifications are the same for children and adults [see indications and usage ( 1 ), dosage and administration ( 2.1 ), and clinical studies ( 14 )]. fourteen patients with spherocytosis (including hereditary) (ages 3-15), two patients with pyruvate kinase deficiency (ages 4 and 6), two patients with dyserythropoietic anemia (ages 10-12) and two patients with hemolytic anemia (ages 8 and 10 years old) were treated with ferriprox in the clinical trial, la38-0411. a us registry established from december 2011 through december 2019, contains 125 patients from 4 to < 17 years old who have received ferriprox and have sickle cell disease. the adverse reactions, including agranulocytosis, seen in the 8 year period of the registry are similar to those seen in the most recent clinical studies. safety and effectiveness of ferriprox tablets have not been established in pediatric patients with chronic iron overload due to blood transfusions who are less than 8 years of age. 8.5 geriatric use clinical studies of deferiprone did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

miscarriage is 2-4% and 15-20%, respectively. data human data post-marketing data available from 39 pregnancies of deferiprone-treated patients and 10 pregnancies of partners of deferiprone-treated patients are as follows: of the 39 pregnancies in deferiprone-treated patients, 23 resulted in healthy newborns, 6 ended in spontaneous abortion, 9 had unknown outcomes, and 1 infant was born with anal atresia, nephroptosis, ventricular septal defect, hemivertebra and urethral fistula. of the 10 pregnancies in partners of deferiprone-treated patients, 5 resulted in healthy newborns, 1 resulted in a healthy newborn with slight hypospadias, 1 was electively terminated, 1 resulted in the intrauterine death of twins, and 2 had unknown outcomes. animal data during organogenesis, pregnant rats and rabbits received deferiprone at oral doses of 0, 30, 80 or 200 mg/kg/day, and 0, 10, 50, or 150 mg/kg/day, respectively. the daily dose was administered as two equal divided doses approximately 7 hours apart. doses of 200 mg/kg/day in rats and 150 mg/kg/day in rabbits, approximately 33% and 49% of the mrhd, respectively, resulted in increased post-implantation loss and reduced fetal weights in the presence of maternal toxicity (reduced maternal body weight and body weight gain in both rats and rabbits; abnormal large placenta at low incidence in rats). the 200 mg/kg/day dose in rats resulted in external, visceral and skeletal fetal malformations such as cranial malformations, cleft palate, limb malrotation, anal atresia, internal hydrocephaly, anophthalmia and fused bones. the dose of 150 mg/kg/day in rabbits resulted in external fetal malformations (partially opened eyes) and minor blood vessel and skeletal variations. in rats, malformations including micrognathia and persistent ductus arteriosus could be observed in the absence of maternal toxicity at doses equal to or greater than 30 and 80 mg/kg/day, approximately 5% and 13% of the mhrd, respectively.

the same for children and adults [see indications and usage ( 1 ), dosage and administration ( 2.1 ), and clinical studies ( 14 )]. fourteen patients with spherocytosis (including hereditary) (ages 3-15), two patients with pyruvate kinase deficiency (ages 4 and 6), two patients with dyserythropoietic anemia (ages 10-12) and two patients with hemolytic anemia (ages 8 and 10 years old) were treated with ferriprox in the clinical trial, la38-0411. a us registry established from december 2011 through december 2019, contains 125 patients from 4 to < 17 years old who have received ferriprox and have sickle cell disease. the adverse reactions, including agranulocytosis, seen in the 8 year period of the registry are similar to those seen in the most recent clinical studies. safety and effectiveness of ferriprox tablets have not been established in pediatric patients with chronic iron overload due to blood transfusions who are less than 8 years of age.

fasted healthy subjects. effect of food following the administration of ferriprox tablets (twice a day) to healthy volunteers, the c max and the auc of deferiprone remain unchanged after a high-fat meal (approximately 1,000 calories, 53% fat, 33% carbohydrates, and 14% protein) compared to fasted conditions. effect of alcohol at 40% (v/v) alcohol concentration in vitro dissolution studies, there was 88% release of deferiprone from a 1,000 mg ferriprox tablet (twice a day) within two hours compared to 4% release of deferiprone within 2 hours in the absence of alcohol. distribution the apparent mean ± sd volume of distribution (v/f) of deferiprone was 97 ± 28 l following oral administration of a 1,000 mg dose of ferriprox tablets (twice a day) with food. elimination the mean ± sd elimination half-life of deferiprone is 1.8 ± 0.3 hours following the administration of ferriprox tablets (twice a day). metabolism deferiprone is metabolized primarily by ugt1a6. the major metabolite of deferiprone is the 3- o -glucuronide, which lacks iron- binding capability. excretion following oral administration, 75% to 90% of the administered dose was recovered in urine (primarily as metabolite) in the first 24 hours. ferriprox tablets (three times a day), 1,000 mg and 500 mg the mean c max and auc of deferiprone was 20 mcg/ml and 50 mcg∙h/ml, respectively, in healthy subjects. the dose proportionality of deferiprone over the approved recommended dosage range is unknown. absorption deferiprone appeared in the blood within 5 to 10 minutes after oral administration. peak serum concentration of deferiprone was reached approximately 1 to 2 hours after a single dose. effect of food no clinically significant differences in the pharmacokinetics of deferiprone were observed following administration with food. elimination the elimination half-life of deferiprone is approximately 2 hours. metabolism deferiprone is metabolized primarily by ugt1a6. the major metabolite of deferiprone is the 3- o -glucuronide, which lacks iron binding capability. excretion following oral administration, 75% to 90% of the administered dose was recovered in urine (primarily as metabolite) in the first 24 hours. specific populations no clinically significant differences in the pharmacokinetics of deferiprone were observed based on sex, race/ethnicity, body weight, mild to severe (egfr 15 to 89 ml/min/1.73 m 2 ) renal impairment, or mild (child pugh class a) to moderate (child pugh class b) hepatic impairment. the effect of age, including geriatric or pediatric populations, end stage renal disease or severe (child pugh class c) hepatic impairment on the pharmacokinetics of deferiprone is unknown. drug interaction studies in vitro studies ugtia6 inhibitors: phenylbutazone (ugt1a6 inhibitor) decreased glucuronidation of deferiprone by up to 78%. polyvalent cations: deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc).

of alcohol. distribution the apparent mean ± sd volume of distribution (v/f) of deferiprone was 97 ± 28 l following oral administration of a 1,000 mg dose of ferriprox tablets (twice a day) with food. elimination the mean ± sd elimination half-life of deferiprone is 1.8 ± 0.3 hours following the administration of ferriprox tablets (twice a day). metabolism deferiprone is metabolized primarily by ugt1a6. the major metabolite of deferiprone is the 3- o -glucuronide, which lacks iron- binding capability. excretion following oral administration, 75% to 90% of the administered dose was recovered in urine (primarily as metabolite) in the first 24 hours. ferriprox tablets (three times a day), 1,000 mg and 500 mg the mean c max and auc of deferiprone was 20 mcg/ml and 50 mcg∙h/ml, respectively, in healthy subjects. the dose proportionality of deferiprone over the approved recommended dosage range is unknown. absorption deferiprone appeared in the blood within 5 to 10 minutes after oral administration. peak serum concentration of deferiprone was reached approximately 1 to 2 hours after a single dose. effect of food no clinically significant differences in the pharmacokinetics of deferiprone were observed following administration with food. elimination the elimination half-life of deferiprone is approximately 2 hours. metabolism deferiprone is metabolized primarily by ugt1a6. the major metabolite of deferiprone is the 3- o -glucuronide, which lacks iron binding capability. excretion following oral administration, 75% to 90% of the administered dose was recovered in urine (primarily as metabolite) in the first 24 hours. specific populations no clinically significant differences in the pharmacokinetics of deferiprone were observed based on sex, race/ethnicity, body weight, mild to severe (egfr 15 to 89 ml/min/1.73 m 2 ) renal impairment, or mild (child pugh class a) to moderate (child pugh class b) hepatic impairment. the effect of age, including geriatric or pediatric populations, end stage renal disease or severe (child pugh class c) hepatic impairment on the pharmacokinetics of deferiprone is unknown. drug interaction studies in vitro studies ugtia6 inhibitors: phenylbutazone (ugt1a6 inhibitor) decreased glucuronidation of deferiprone by up to 78%. polyvalent cations: deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc).

d in rats. sperm counts, motility and morphology were unaffected by treatment with deferiprone. there were no effects observed on male or female fertility or reproductive function at the highest dose which was 25% of the mrhd.

otility and morphology were unaffected by treatment with deferiprone. there were no effects observed on male or female fertility or reproductive function at the highest dose which was 25% of the mrhd.

one year of starting therapy. data from a total of 236 patients were analyzed. of the 224 patients with thalassemia who received deferiprone monotherapy and were eligible for serum ferritin analysis, 105 (47%) were male and 119 (53%) were female. the mean age of these patients was 18.2 years (range 2 to 62; 91 patients were <17). for the patients in the analysis, the endpoint of at least a 20% reduction in serum ferritin was met in 50% (of 236 subjects), with a 95% confidence interval of 43% to 57%. a small number of patients with thalassemia and iron overload were assessed by measuring the change in the number of milliseconds (ms) in the cardiac mri t2* value before and after treatment with deferiprone for one year. there was an increase in cardiac mri t2* from a mean at baseline of 11.8 ± 4.9 ms to a mean of 15.1 ± 7.0 ms after approximately one year of treatment. the clinical significance of this observation is not known. 14.2 transfusional iron overload in patients with sickle cell disease and other anemias study la38-0411, an actively-controlled non-inferiority study compared the efficacy of ferriprox to that of deferoxamine in patients with sickle cell disease and other transfusion-dependent anemias by evaluating liver iron concentration (lic). the efficacy of ferriprox was established based upon the change in lic from baseline after 12 months of ferriprox (75 or 99 mg/kg/day) compared to deferoxamine (20 or 40 mg/kg (pediatric patients); 40 or 50 mg/kg (adult patients)). patient enrollment was stopped following an interim analysis. after adjusting for the type i (alpha) error, the non-inferiority criterion was established as the upper limit of the 96.01% confidence interval for the difference between treatments being ≤2 mg/g dry weight (dw). data from 185 patients (122 on ferriprox and 63 on deferoxamine) were available. among the 122 ferriprox treated patients, the mean age was 15.9 years (range 3-46); 57.4% were male; 75.4% were white, 17.2% were black and 7.4% were multi-racial; 85% were diagnosed with sickle cell disease and 15% with other anemias. over 12 months, the least squares estimate of mean decrease from baseline in lic was 4.13 ± 0.50 mg/g dw for ferriprox and 4.38 ± 0.59 mg/g dw for deferoxamine, and the non-inferiority criterion was met. upon completion of the first year of therapy in the non inferiority study, 89 patients from the ferriprox group opted to continue with treatment and 45 from the deferoxamine group opted to switch to ferriprox treatment. this group continued for up to an additional 2 years. lic continued to decrease over time, with the mean value dropping from 14.93 mg/g dw at baseline to 12.30 mg/g dw after one year of treatment, to 11.19 mg/g dw after two years of treatment, and to 10.45 mg/g dw after three years of treatment.

 on one side and are plain on the other. they are provided in hdpe bottles. 1,000 mg film-coated tablets, 50 tablets ndc 10122-103-05 store at 20°c to 25°c (68°f to 77°f); excursions permitted to 15°c to 30°c (59°f to 86°f) [see usp controlled room temperature]. keep the bottle tightly closed to protect from moisture. ferriprox tablets, 500 mg ferriprox ® tablets (deferiprone) are white to off-white capsule-shaped tablets, film-coated, and have a functional score imprinted with “apo” score “500” on one side and are plain on the other. they are provided in hdpe bottles. 500 mg film-coated tablets, 100 tablets ndc 10122-100-10 store at 20°c to 25°c (68°f to 77°f); excursions permitted to 15°c to 30°c (59°f to 86°f) [see usp controlled room temperature].

ose at midday, and the third dose in the evening. clinical experience suggests that taking ferriprox with meals may reduce nausea. ferriprox tablets, 500 mg: store in the originally supplied bottle, closed tightly to protect from moisture. advise patients to take the first dose of ferriprox in the morning, the second dose at midday, and the third dose in the evening. clinical experience suggests that taking ferriprox with meals may reduce nausea. if a dose of this medicine has been missed, take it as soon as possible. however, if it is almost time for the next dose, skip the missed dose and go back to the regular dosing schedule. do not catch-up or double doses. inform patients of the risks of developing agranulocytosis and the need for regular blood testing before and during their treatment to monitor for decreases in their anc. instruct them to immediately interrupt therapy and report to their physician if they experience any symptoms of infection such as fever, sore throat or flu-like symptoms [see dosage and administration ( 2.1 ) and warnings and precautions ( 5.1 )] in order to check their anc within 24 hours. advise them if they are unable to reach their physician, seek care from another provider so as not to delay medical care. inform patients of the risk of abnormal liver transaminases and the need for regular blood testing before and during their treatment to monitor for increases in alt [see dosage and administration ( 2.1 ) and warnings and precautions ( 5.2 )] . inform patients of the risk of zinc deficiency and the need for regular blood testing before and during their treatment to monitor for reductions in zinc [see dosage and administration ( 2.1 ) and warnings and precautions ( 5.3 )] . advise patients to contact their physician in the event of overdose. inform patients that their urine might show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. this is a very common sign of the desired effect, and it is not harmful. embryo-fetal toxicity advise pregnant women and females of reproductive potential of the potential risk to a fetus. advise females to inform their healthcare provider of a known or suspected pregnancy [see warnings and precautions ( 5.4 ) and use in specific populations ( 8.1 )] . advise female patients of reproductive potential to use effective contraception during treatment with ferriprox and for at least six months after the last dose [see use in specific populations ( 8.1 , 8.3 )] . advise males with female partners of reproductive potential to use effective contraception during treatment with ferriprox and for at least three months after the last dose [see use in specific populations ( 8.3 ) and nonclinical toxicology ( 13.1 )] . lactation advise females not to breastfeed during treatment with ferriprox and for at least 2 weeks after the last dose [see use in specific populations ( 8.2 )] . distributed by chiesi usa, inc., cary, nc 27518. manufactured by apotex inc., toronto, ontario, canada, m9l 1t9. ctfd-032-0521-00-spl